Japan · Delayed Price · Currency is JPY Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of JPY 666.16 billion. The enterprise value is 750.18 billion.
| Market Cap | 666.16B |
| Enterprise Value | 750.18B |
Important Dates
The next confirmed earnings date is Friday, October 30, 2026.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sumitomo Pharma has 448.59 million shares outstanding. The number of shares has increased by 2.41% in one year.
| Current Share Class | 448.59M |
| Shares Outstanding | 448.59M |
| Shares Change (YoY) | +2.41% |
| Shares Change (QoQ) | +9.65% |
| Owned by Insiders (%) | 0.03% |
| Owned by Institutions (%) | 18.72% |
| Float | 238.43M |
Valuation Ratios
The trailing PE ratio is 5.36 and the forward PE ratio is 6.94.
| PE Ratio | 5.36 |
| Forward PE | 6.94 |
| PS Ratio | 1.40 |
| PB Ratio | 1.63 |
| P/TBV Ratio | 18.10 |
| P/FCF Ratio | 10.98 |
| P/OCF Ratio | 10.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.46, with an EV/FCF ratio of 12.37.
| EV / Earnings | 6.66 |
| EV / Sales | 1.58 |
| EV / EBITDA | 10.46 |
| EV / EBIT | 14.19 |
| EV / FCF | 12.37 |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 0.39.
| Current Ratio | 1.21 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | 2.35 |
| Debt / FCF | 2.65 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 38.53% and return on invested capital (ROIC) is 10.26%.
| Return on Equity (ROE) | 38.53% |
| Return on Assets (ROA) | 3.92% |
| Return on Invested Capital (ROIC) | 10.26% |
| Return on Capital Employed (ROCE) | 8.49% |
| Weighted Average Cost of Capital (WACC) | 5.45% |
| Revenue Per Employee | 123.90M |
| Profits Per Employee | 29.40M |
| Employee Count | 4,980 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 2.52 |
Taxes
| Income Tax | -5.95B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.15% in the last 52 weeks. The beta is 0.46, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +1.15% |
| 50-Day Moving Average | 1,385.97 |
| 200-Day Moving Average | 1,936.57 |
| Relative Strength Index (RSI) | 68.04 |
| Average Volume (20 Days) | 3,607,140 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of JPY 474.79 billion and earned 112.66 billion in profits. Earnings per share was 276.88.
| Revenue | 474.79B |
| Gross Profit | 261.08B |
| Operating Income | 49.51B |
| Pretax Income | 106.71B |
| Net Income | 112.66B |
| EBITDA | 68.34B |
| EBIT | 49.51B |
| Earnings Per Share (EPS) | 276.88 |
Balance Sheet
The company has 76.64 billion in cash and 160.66 billion in debt, with a net cash position of -84.02 billion or -187.29 per share.
| Cash & Cash Equivalents | 76.64B |
| Total Debt | 160.66B |
| Net Cash | -84.02B |
| Net Cash Per Share | -187.29 |
| Equity (Book Value) | 408.56B |
| Book Value Per Share | 910.75 |
| Working Capital | 55.61B |
Cash Flow
In the last 12 months, operating cash flow was 64.46 billion and capital expenditures -3.80 billion, giving a free cash flow of 60.67 billion.
| Operating Cash Flow | 64.46B |
| Capital Expenditures | -3.80B |
| Depreciation & Amortization | 18.82B |
| Net Borrowing | -151.88B |
| Free Cash Flow | 60.67B |
| FCF Per Share | 135.24 |
Margins
Gross margin is 54.99%, with operating and profit margins of 10.43% and 23.73%.
| Gross Margin | 54.99% |
| Operating Margin | 10.43% |
| Pretax Margin | 22.47% |
| Profit Margin | 23.73% |
| EBITDA Margin | 14.39% |
| EBIT Margin | 10.43% |
| FCF Margin | 12.78% |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.00% |
| Buyback Yield | -2.41% |
| Shareholder Yield | -2.41% |
| Earnings Yield | 16.91% |
| FCF Yield | 9.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Sumitomo Pharma is 2,071.43, which is 33.73% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,071.43 |
| Price Target Difference | 33.73% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 10.80% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of 2.17 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 6 |